Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07600190 · ClinicalTrials.gov registry record · Phase 1
Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Not yet
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT07600190: Clinical Trial Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
NCT07600190 is a Phase 1 study that has not yet begun recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 60 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07600190, a Phase 1 study, has not yet begun recruiting, sponsored by University of North Carolina, Chapel Hill.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, triggering treatment dosing over a 26 week period. Key feasibility questions will be assessed in this pilot study to inform trial design and sample size selection for a future multi-site phase II clinical trial testing anakinra as a rescue treatment for moderate asthma exacerbations.
Primary Outcome
Area under the curve (AUC) of the absolute change from baseline, over the period of treatment day 1 through 10 days post-treatment day 1, calculated using the trapezoidal method, and comparing Anakinra to placebo treatment.
Interventions
- DRUG Anakinra 100 Mg/0.67 Ml Inj Syringe
- DRUG Saline Placebo/0.67 Ml Inj Syringe
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
What is known before NCT07600190 opens enrollment
NCT07600190 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Anakinra 100 Mg/0.67 Ml Inj Syringe is the first listed.
NCT07600190 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07600190 about?
NCT07600190 is a clinical study titled "Anakinra Rescue Treatment for Moderate Asthma Attacks (ARTMA)". In this single center, interventional pilot study, 40 participants at high risk for future exacerbation will be randomized to anakinra (v. placebo control) treatment for home administration as part of an asthma action plan (AAP) and monitored through their first moderate asthma exacerbation, trigger...
What is the current status of trial NCT07600190?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2026-06-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07600190?
The interventions under investigation include: Anakinra 100 Mg/0.67 Ml Inj Syringe (DRUG), Saline Placebo/0.67 Ml Inj Syringe (DRUG).
Who is sponsoring clinical trial NCT07600190?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07600190's enrollment target sits among peer trials
60 831st of 2000 higher than 1,106 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI